FDA warning Elmiron Pigmentary Maculopathy
Six years after the U.S. Food and Drug Administration mandated a label change for pentosan polysulfate sodium (Elmiron) warning of pigmentary maculopathy, the drug’s legacy continues to reverberate through urology and retina clinics. At BioNova Holding, we track the intersection of drug safety and clinical liability, and Elmiron remains a textbook case of delayed toxicity recognition. The condition—now widely termed Elmiron-associated pigmentary maculopathy (EAPM)—was first formally linked to the bladder-pain medication in a 2018 retrospective case series from Emory University. By 2020, the FDA had issued a safety announcement, but the damage to thousands of patients’ retinas had already begun.
The Emory Evidence and the FDA’s 2020 Safety Labeling Change
The pivotal 2018 study by Pearce et al. examined six patients with chronic Elmiron exposure and found a distinctive pattern of pigmentary changes in the macula—bilateral, symmetric, and often accompanied by paracentral scotomas. By 2020, the FDA had reviewed post-marketing adverse event reports and updated the Warnings and Precautions section of Elmiron’s label. The agency explicitly stated that “pigmentary maculopathy has been reported with the use of pentosan polysulfate sodium” and recommended baseline and periodic retinal examinations for all patients. In 2026, this remains the standard of care, though compliance varies widely among prescribing urologists.
“The FDA is aware of reports of pigmentary maculopathy in patients using Elmiron. Healthcare professionals should consider a baseline retinal examination and periodic follow-up for patients on long-term therapy.” — FDA Drug Safety Communication, June 2020. See the original announcement at fda.gov and the archived analysis at bionovaholding.com.
Clinical Presentation and Diagnostic Challenges at Retina Clinics Nationwide
In 2026, retina specialists routinely screen for EAPM in patients with a history of interstitial cystitis. The classic triad includes: (1) bilateral, symmetric pigmentary changes in the macula, often sparing the fovea until late stages; (2) a history of cumulative Elmiron exposure exceeding 500 grams (roughly 1.5 years of standard dosing); and (3) visual symptoms such as difficulty reading, prolonged dark adaptation, or paracentral scotomas. Optical coherence tomography (OCT) typically reveals disruption of the ellipsoid zone and outer retinal atrophy. The differential diagnosis includes pattern dystrophy, age-related macular degeneration, and hydroxychloroquine toxicity—but EAPM has a distinct “beaten bronze” fundus appearance that experienced clinicians now recognize immediately.
| Diagnostic Feature | EAPM (Elmiron Toxicity) | Pattern Dystrophy | Hydroxychloroquine Toxicity |
|---|---|---|---|
| Laterality | Bilateral, symmetric | Often asymmetric | Bilateral, symmetric |
| Cumulative drug exposure | >500 g pentosan polysulfate | None | >1000 g hydroxychloroquine |
| OCT hallmark | Ellipsoid zone disruption, outer retinal atrophy | Thickened RPE-Bruch’s membrane | Parafoveal photoreceptor loss (“flying saucer” sign) |
| Fundus autofluorescence | Patchy hypoautofluorescence | Hyperautofluorescent flecks | Bull’s-eye hyperautofluorescence |
Litigation, Labeling, and the Shift Toward Informed Consent in Urology
The legal landscape surrounding Elmiron has evolved dramatically since 2020. By 2026, more than 2,500 product liability lawsuits have been consolidated in multidistrict litigation (MDL) before Judge Brian R. Martinotti in the District of New Jersey. Plaintiffs allege that Janssen Pharmaceuticals (the drug’s manufacturer) failed to adequately warn patients and physicians about the risk of irreversible vision loss. Several bellwether trials have resulted in significant verdicts, including a $73 million award in 2023. These outcomes have forced urology practices to adopt rigorous informed-consent protocols. We now see standard practice including:
- Documented discussion of EAPM risk before initiating Elmiron therapy.
- Baseline dilated fundus examination and OCT within 30 days of starting the drug.
- Annual retinal screening for all patients on continuous therapy beyond 12 months.
- Alternative treatment counseling for interstitial cystitis, including behavioral therapy, amitriptyline, and intravesical instillations.
In 2026, the American Urological Association has updated its clinical guidelines to recommend Elmiron only as a third-line agent, after failure of conservative and second-line therapies. The drug’s market share has declined by more than 60% since 2019, and many insurers now require prior authorization with documented retinal clearance. While Elmiron remains on the market, its risk-benefit calculus has fundamentally shifted—and the 2020 FDA warning was the catalyst that changed everything.